Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coya Therapeutics (COYA) Income from Continuing Operations (2023 - 2025)

Historic Income from Continuing Operations for Coya Therapeutics (COYA) over the last 3 years, with Q3 2025 value amounting to -$2.4 million.

  • Coya Therapeutics' Income from Continuing Operations rose 4533.17% to -$2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.9 million, marking a year-over-year decrease of 8825.45%. This contributed to the annual value of -$14.9 million for FY2024, which is 8629.31% down from last year.
  • As of Q3 2025, Coya Therapeutics' Income from Continuing Operations stood at -$2.4 million, which was up 4533.17% from -$6.1 million recorded in Q2 2025.
  • Coya Therapeutics' Income from Continuing Operations' 5-year high stood at $1.8 million during Q4 2023, with a 5-year trough of -$7.3 million in Q1 2025.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$3.6 million (2023), whereas its average is -$3.7 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first crashed by 32479.04% in 2024, then soared by 4533.17% in 2025.
  • Over the past 3 years, Coya Therapeutics' Income from Continuing Operations (Quarter) stood at $1.8 million in 2023, then crashed by 324.79% to -$4.1 million in 2024, then surged by 40.37% to -$2.4 million in 2025.
  • Its Income from Continuing Operations was -$2.4 million in Q3 2025, compared to -$6.1 million in Q2 2025 and -$7.3 million in Q1 2025.